Thailand - In January 2024, the Court of Appeal for Specialized Cases upheld a ruling that found two local pharmaceutical companies, Unisun and Medline, jointly liable for infringing H. Lundbeck A/S's patent for antidepressant escitalopram. The court confirmed the lower court's finding that the companies manufactured, sold, and distributed the drug in Thailand without authorization. The companies were ordered to pay Lundbeck 106,500 Danish Krone (approximately US$15,500) in damages, plus legal costs and court fees.
The case began in June 2020, when Lundbeck initiated legal action against Unisun and Medline for allegedly manufacturing, selling, and distributing escitalopram in Thailand without authorization. Lundbeck also claimed the companies had registered escitalopram as a Thai innovation with the National Science and Technology Development Agency (NSTDA), enabling them to bypass the auction process and sell the drug directly to hospitals and state agencies, thereby undercutting Lundbeck's market share.
Lundbeck initially sought substantial damages exceeding 4 million Danish Krone (around US$584,000) and a range of remedies, including halting the infringement, destruction of the infringing products, and withdrawal of the innovation record with the NSTDA. However, the Central Intellectual Property and International Trade Court awarded Lundbeck a significantly lower sum of 1.1 million Thai Baht (approximately US$30,100), including 500,000 THB for enforcement costs and 600,000 THB for lost profits. The court denied Lundbeck's other requests, such as the withdrawal of the NSTDA record, likely due to the expiration of Lundbeck's Thai patent.
Dissatisfied with the initial ruling, both companies appealed. Unisun and Medline contested the amount awarded for lost profits, arguing it was excessive, while Lundbeck sought a higher overall compensation. The Court of Appeal, however, largely upheld the original ruling, adjusting the award to Danish Krone at Lundbeck's request.
QUAN, Nguyen Vu | Partner, IP Attorney
Related Articles: